First-Line Pembrolizumab Monotherapy Improves Progression-Free Survival in dMMR Endometrial Cancer

New findings from the Phase 3 KEYNOTE-C93 trial, presented at the 2026 ESMO Congress and published in The Lancet, demonstrate that first-line pembrolizumab (Keytruda) monotherapy significantly improved progression-free survival compared with standard chemotherapy in patients with mismatch repair-deficient (dMMR) advanced or recurrent endometrial cancer.